Mortality Related to Severe Sepsis and Septic Shock Among Critically III Patients in Australia and New Zealand, 2000-2012

被引:1282
作者
Kaukonen, Kirsi-Maija [1 ,2 ]
Bailey, Michael [1 ]
Suzuki, Satoshi [3 ]
Pilcher, David [1 ,4 ,5 ]
Bellomo, Rinaldo [1 ,3 ]
机构
[1] Monash Univ, ANZIC RC, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
[2] Univ Helsinki, Cent Hosp, Intens Care Unit, Crit Care Res Grp, Helsinki, Finland
[3] Austin Hlth, Intens Care Unit, Heidelberg, Vic 3084, Australia
[4] ANZICS Ctr Outcome & Resource Evaluat CORE, Melbourne, Vic, Australia
[5] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2014年 / 311卷 / 13期
基金
芬兰科学院;
关键词
INTENSIVE INSULIN THERAPY; HYDROXYETHYL STARCH; HOSPITAL MORTALITY; SURVIVING SEPSIS; UNITED-STATES; RESUSCITATION; ADULTS; RISK; HYDROCORTISONE; IMPLEMENTATION;
D O I
10.1001/jama.2014.2637
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
IMPORTANCE Severe sepsis and septic shock are major causes of mortality in intensive care unit (ICU) patients. It is unknown whether progress has been made in decreasing their mortality rate. OBJECTIVE To describe changes in mortality for severe sepsis with and without shock in ICU patients. DESIGN, SETTING, AND PARTICIPANTS Retrospective, observational study from 2000 to 2012 including 101 064 patients with severe sepsis from 171 ICUs with various patient case mix in Australia and New Zealand. MAIN OUTCOMES AND MEASURES Hospital outcome (mortality and discharge to home, to other hospital, or to rehabilitation). RESULTS Absolute mortality in severe sepsis decreased from 35.0% (95% CI, 33.2%-36.8%; 949/2708) to 18.4% (95% CI, 17.8%-19.0%; 2300/12 512; P<.001), representing an overall decrease of 16.7% (95% CI, 14.8%-18.6%), an annual rate of absolute decrease of 1.3%, and a relative risk reduction of 47.5% (95% CI, 44.1%-50.8%). After adjusted analysis, mortality decreased throughout the study period with an odds ratio (OR) of 0.49 (95% CI, 0.46-0.52) in 2012, using the year 2000 as the reference (P<.001). The annual decline in mortality did not differ significantly between patients with severe sepsis and those with all other diagnoses (OR, 0.94 [95% CI, 0.94-0.95] vs 0.94 [95% CI, 0.94-0.94]; P = .37). The annual increase in rates of discharge to home was significantly greater in patients with severe sepsis compared with all other diagnoses (OR, 1.03 [95% CI, 1.02-1.03] vs 1.01 [95% CI, 1.01-1.01]; P<.001). Conversely, the annual increase in the rate of patients discharged to rehabilitation facilities was significantly less in severe sepsis compared with all other diagnoses (OR, 1.08 [95% CI, 1.07-1.09] vs 1.09 [95% CI, 1.09-1.10]; P<.001). In the absence of comorbidities and older age, mortality was less than 5%. CONCLUSIONS AND RELEVANCE In critically ill patients in Australia and New Zealand with severe sepsis with and without shock, there was a decrease in mortality from 2000 to 2012. These findings were accompanied by changes in the patterns of discharge to home, rehabilitation, and other hospitals.
引用
收藏
页码:1308 / 1316
页数:9
相关论文
共 45 条
[1]
Delta inflation: A bias in the design of randomized controlled trials in critical care medicine [J].
Aberegg S.K. ;
Richards D.R. ;
O'Brien J.M. .
Critical Care, 14 (2)
[2]
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[4]
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[5]
Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock:: a randomised trial [J].
Annane, Djillali ;
Vignon, Philippe ;
Renault, Alain ;
Bollaert, Pierre-Edouard ;
Charpentier, Claire ;
Martin, Claude ;
Troche, Gilles ;
Ricard, Jean-Damien ;
Nitenberg, Gerard ;
Papazian, Laurent ;
Azoulay, Elie ;
Bellissant, Eric .
LANCET, 2007, 370 (9588) :676-684
[6]
Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults A Randomized Controlled Trial [J].
Annane, Djillali ;
Cariou, Alain ;
Maxime, Virginie ;
Azoulay, Elie ;
D'honneur, Gilles ;
Timsit, Jean Francois ;
Cohen, Yves ;
Wolf, Michel ;
Fartoukh, Muriel ;
Adrie, Christophe ;
Santre, Charles ;
Bollaert, Pierre Edouard ;
Mathonet, Armelle ;
Amathieu, Roland ;
Tabah, Alexis ;
Clec'h, Christophe ;
Mayaud, Julien ;
Lejeune, Julie ;
Chevret, Sylvie .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (04) :341-348
[7]
[Anonymous], QUICKSTATS ABOUT NEW
[8]
[Anonymous], 3101 0 AUSTRALIAN DE
[9]
Patient and hospital characteristics associated with inpatient severe sepsis mortality in California, 2005-2010 [J].
Banta, Jim E. ;
Joshi, Kamlesh P. ;
Beeson, Lawrence ;
Nguyen, H. Bryant .
CRITICAL CARE MEDICINE, 2012, 40 (11) :2960-2966
[10]
Bellomo R, 2011, CRIT CARE RESUSC, V13, P211